Researchers at Boston University College of Health & Rehabilitation Sciences: Sargent College have identified a combinatorial therapeutic approach that has proven effective in treating muscular dystrophy in a mouse model.
The findings, published in Human Molecular Genetics, represent a paradigm shift for the treatment of muscular dystrophy as well as a host of other disabling and devastating muscle diseases.
The study was led by Mahasweta Girgenrath, PhD, assistant professor and director of the Muscle Disorders and Regenerative Biology Laboratory at BU Sargent College’s Department of Health Sciences. Boston University (BU) researchers and postdoctoral fellows Jenny Yamauchi, Ajay Kumar, Lina Duarte, and Thomas Mehuron were collaborators on this study.
Muscular Dystrophy type 1A (MDC1A) is the second most common form of congenital muscular dystrophy. Patients with this disease have poor muscle tone at birth, extremely compromised neuromuscular function, and are rarely able to walk independently. Most patients with MDC1A succumb to a premature death due to either respiratory complications or failure to thrive. Although significant strides have been made towards understanding the molecular and biochemical mechanisms underlying MDC1A, there remains no effective therapy in place to combat this lethal disease.
The research team, led by Girgenrath, hypothesized that the complex pathology seen in MDC1A may be the result of dysregulation of multiple cellular functions and processes, meaning that strategies which simultaneously target several of those mechanisms might lead to a reduction of symptoms.
“Very few studies have utilized the power of combinatorial therapy in the context of muscular dystrophy.” said Professor Girgenrath, the study’s corresponding author. “While most MD treatments are single-target therapies, we’re delving into combinations of different therapies to target multiple pathways.”
The research team studied the outcome of combining the following single mode treatments: increasing regeneration, by overexpressing muscle specific insulin like growth factor-1, IGF-1 and preventing cell death, by inhibiting the expression of Bax, a pro-apoptotic protein. In addition, to test the translational potential of this combination therapy, the researchers systemically treated Bax deficient dystrophic mice with recombinant human IGF-1 (IPLEX TM, manufactured by Insmed Inc).
By combining these two therapies, researchers found that in addition to increased body and muscle weight, mice showed enhanced locomotory capacities and remarkable improvement in muscle pathology. The most impressive outcome was the significant resolution of inflammation and fibrosis, not seen with single mode therapies. The research team concluded that the use of this combination therapy is an effective treatment for MDC1A, highlighting a compelling argument that a combinatorial approach has a synergistic benefit and could have the potential of treating patients with congenital muscular dystrophy.
The Latest Bing News on:
Novel Therapy to Treat Muscular Dystrophy
- Stealth BioTherapeutics Receives Orphan Drug Designation from FDA for Elamipretide for Treatment of Duchenne Muscular Dystrophyon May 12, 2022 at 5:47 am
Office of Orphan Products Development has granted Orphan Drug Designation to elamipretide for the treatment of patients with Duchenne muscular dystrophy (DMD). The company also announced that the ...
- Stealth BioTherapeutics Receives Orphan Drug Designation from FDA for Elamipretide for Treatment of Duchenne Muscular Dystrophyon May 12, 2022 at 5:47 am
Office of Orphan Products Development has granted Orphan Drug Designation to elamipretide for the treatment of patients with Duchenne muscular dystrophy (DMD). The company also announced that the ...
- Stealth BioTherapeutics Receives Orphan Drug Designation from FDA for Elamipretide for Treatment of Duchenne Muscular Dystrophyon May 12, 2022 at 4:55 am
Office of Orphan Products Development has granted Orphan Drug Designation to elamipretide for the treatment of patients with Duchenne muscular dystrophy (DMD). The company also announced that ...
- Entrada Therapeutics Presents New Data Supporting its Growing Pipeline of Endosomal Escape Vehicle (EEV™) Therapeutics at TIDES USA 2022on May 11, 2022 at 9:30 am
New non-human primate data demonstrate a durability of response through 12 weeks for lead clinical candidate, ENTR-601-44, for the potential treatment of Duchenne muscular dystrophy Second ...
- Entrada Therapeutics Presents New Data Supporting its Growing Pipeline of Endosomal Escape ...on May 11, 2022 at 8:15 am
Entrada expects to file an IND application with the U.S. FDA for ENTR-601-44 for the potential treatment of patients with Duchenne muscular dystrophy ... is the second novel clinical candidate ...
- Entrada Therapeutics Presents New Data Supporting its Growing Pipeline of Endosomal Escape Vehicle (EEV™) Therapeutics at TIDES USA 2022on May 11, 2022 at 7:30 am
ENTR-601-44, a proprietary Endosomal Escape Vehicle (EEV™)-conjugated phosphorodiamidate morpholino oligomer, is the first novel ... treatment of patients with Duchenne muscular dystrophy ...
- Novel Exon-skipping Therapy Mix May Be Able to Treat Over 40% of DMDon May 10, 2022 at 6:48 am
An international team of scientists has developed a novel exon-skipping therapy mixture that has the potential to treat more than 40% of people with Duchenne muscular dystrophy (DMD). The therapy was ...
- Contract manufacturing issue holds up Regenxbio’s Duchenne gene therapy trialon May 10, 2022 at 4:17 am
Regenxbio says it is to delay dosing of patients in its DMD gene therapy clinical trial following a quality issue at an unnamed third-party contract manufacturer.
The Latest Google Headlines on:
Novel Therapy to Treat Muscular Dystrophy
The Latest Bing News on:
Muscular dystrophy
- Google Doodle honors queer, Korean American disability rights activiston May 19, 2022 at 5:29 pm
Milbern, who had muscular dystrophy, dedicated most of her life to advocating for disability justice and challenging the mainstream disability rights movement for marginalizing people of color and ...
- Dutch Bros holds 16th annual fundraiser Friday to support the fight against ALSon May 19, 2022 at 10:55 am
The drive-thru coffee company will donate a portion of proceeds from all of its more than 550 shops to the Muscular Dystrophy Association.
- UC Davis Health helps find 'genuine breakthrough' through clinical trial for muscular dystrophy patientson May 19, 2022 at 8:41 am
UC Davis is participating in a clinical trial which has found 'tremendous benefits' from stem cell therapy in improving heart function and arm strength.
- UC Davis helps find a 'genuine breakthrough' through clincal trial for muscular dystrophy patientson May 19, 2022 at 8:32 am
UC Davis participated in a clinical trial which has found "tremendous benefits" from stem cell therapy in improving heart function and arm strength for patients.
- Youngster with muscular dystrophy enjoys new wheelchair accessible swing at Sunderland playparkon May 19, 2022 at 5:46 am
Will Calvert's aunt Angela, campaigned for the equipment to be installed at Hylton Castle park for the best part of a year ...
- Obesity and loss of ambulation are associated with lower extremity oedema in Duchenne muscular dystrophyon May 12, 2022 at 5:00 pm
Patients with Duchenne muscular dystrophy have multiple risk factors for lower extremity oedema. This study sought to define the frequency and predictors of oedema. Patients aged ...
- Stealth BioTherapeutics Receives Orphan Drug Designation from FDA for Elamipretide for Treatment of Duchenne Muscular Dystrophyon May 12, 2022 at 5:07 am
Pre-IND meeting request granted by FDA's Division of Neurology IBOSTON, May 12, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), ...
- Parent Project Muscular Dystrophy Announces Pediatric Certified Duchenne Care Center, Helen DeVos Children’s Hospitalon May 11, 2022 at 7:19 am
Leading Duchenne Organization Expands Certification of Clinics that Provide Optimal Care for People with Duchenne Muscular Dystrophy with 1st Clinic in Michigan WASHINGTON, May 11, 2022 /PRNewswire/ - ...
- Muscular dystrophy drug developer PepGen stock jumps 10% following $108M IPOon May 6, 2022 at 11:36 am
The company, which has been developing a treatment for Duchenne muscular dystrophy, offered 9M shares at $12 per share. Underwriters were granted a 30-day option to buy up to 1.35M shares at the ...
- Muscular dystrophy startup goes public in $108M IPOon May 6, 2022 at 10:05 am
Founded in 2018, PepGen is developing ogleonucleotide medicines for neurodegenerative diseases, with an initial focus on Duchenne muscular dystrophy and myotonic dystrophy Type 1. Its lead drug ...